NO20073414L - Monoklonale antistoffer mot angiopotetin-lignede protein 4 (ANGPTL4) - Google Patents

Monoklonale antistoffer mot angiopotetin-lignede protein 4 (ANGPTL4)

Info

Publication number
NO20073414L
NO20073414L NO20073414A NO20073414A NO20073414L NO 20073414 L NO20073414 L NO 20073414L NO 20073414 A NO20073414 A NO 20073414A NO 20073414 A NO20073414 A NO 20073414A NO 20073414 L NO20073414 L NO 20073414L
Authority
NO
Norway
Prior art keywords
monoclonal antibodies
angptl4
angiopotetin
protein
neutralizing
Prior art date
Application number
NO20073414A
Other languages
English (en)
Norwegian (no)
Inventor
E-Chiang Lee
Gregory M Landes
Kuy Chung
Ling Chen
Urvi Desai
David Reed Powell
Seokjoo Hong
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of NO20073414L publication Critical patent/NO20073414L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20073414A 2005-01-07 2007-07-03 Monoklonale antistoffer mot angiopotetin-lignede protein 4 (ANGPTL4) NO20073414L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64202205P 2005-01-07 2005-01-07
PCT/US2006/000184 WO2006074228A1 (en) 2005-01-07 2006-01-06 Monoclonal antibodies against angiopoietin-like protein 4 (angptl4 )

Publications (1)

Publication Number Publication Date
NO20073414L true NO20073414L (no) 2007-10-02

Family

ID=36177590

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073414A NO20073414L (no) 2005-01-07 2007-07-03 Monoklonale antistoffer mot angiopotetin-lignede protein 4 (ANGPTL4)

Country Status (14)

Country Link
US (3) US7655762B2 (pt)
EP (1) EP1846452B1 (pt)
JP (1) JP5366406B2 (pt)
KR (1) KR101387781B1 (pt)
CN (1) CN101128485B (pt)
AU (1) AU2006204001B2 (pt)
BR (1) BRPI0606432A2 (pt)
CA (1) CA2594233C (pt)
EA (1) EA016185B1 (pt)
IL (1) IL184235A (pt)
MX (1) MX2007008256A (pt)
NO (1) NO20073414L (pt)
WO (1) WO2006074228A1 (pt)
ZA (1) ZA200705980B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
HUE029170T2 (en) * 2004-07-20 2017-03-28 Genentech Inc Preparations and methods for the use of angiopoietin-like protein 4
SI1771474T1 (sl) * 2004-07-20 2010-06-30 Genentech Inc Inhibitorji angiopoetinu podobnega proteina kombinacije in njihova uporaba
ZA200904022B (en) 2006-12-08 2010-08-25 Lexicon Pharmaceuticals Inc Monoclonal antibodies against ANGPTL3
EP2488640B1 (en) * 2009-10-14 2018-09-26 Nanyang Technological University Antiproliferative agent
JO3274B1 (ar) 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
JP6059202B2 (ja) * 2011-04-08 2017-01-11 アクセス ビジネス グループ インターナショナル リミテッド ライアビリティ カンパニー 逆巻き誘導電源
CN102242198A (zh) * 2011-05-25 2011-11-16 信阳师范学院 通过angptl4基因多态性进行牛育种方法
CN107536847A (zh) * 2011-08-08 2018-01-05 南洋理工大学 血管生成素样4及其在调节细胞渗漏中的用途
WO2013151664A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
EP2838558A1 (en) * 2012-04-16 2015-02-25 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor
GB201301313D0 (en) * 2013-01-25 2013-03-06 Univ Singapore Respiratory Tract Infections
ES2819865T3 (es) 2014-01-07 2021-04-19 Bioatla Llc Proteínas dirigidas a ortólogos
TW201613977A (en) * 2014-08-07 2016-04-16 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
EA201790336A1 (ru) * 2014-08-07 2017-06-30 Новартис Аг Антитела к ангиопоэтинподобному белку 4 и способы применения
PT3370768T (pt) * 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
JP7577654B2 (ja) * 2018-11-13 2024-11-05 リピゴン ファーマスーティカルス アー・ベー 脂肪酸代謝の調節に影響を与えるａｎｇｐｔｌ４オリゴヌクレオチド
US20220389088A1 (en) * 2019-10-29 2022-12-08 University Of Florida Research Foundation, Incorporated Anti-angiopoietin-like 4 (angptl4) antibodies and methods of use
US12563444B1 (en) * 2021-03-04 2026-02-24 Cable Television Laboratories, Inc. Systems and methods for access traffic steering, switching, and splitting with user equipment having multiple identities
JP2024535852A (ja) * 2021-09-17 2024-10-02 アルナイラム ファーマシューティカルズ， インコーポレイテッド ＡＮＧＰＴＬ４をサイレンシングするためのｉＲＮＡ組成物および方法
CN115708872A (zh) * 2022-11-03 2023-02-24 中国科学院深圳先进技术研究院 抗血管生成素样蛋白4抗体在制备抑制炎症因子表达的药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
AU4643699A (en) * 1998-06-24 2000-01-10 Compugen Ltd. Angiopoietin-like growth factor sequences
WO2001077151A2 (en) 2000-04-07 2001-10-18 Millennium Pharmaceuticals, Inc. Fdrg proteins and nucleic acid molecules and uses therefor
NL1017421C2 (nl) 2001-02-21 2002-01-15 Synthon Bv Werkwijze voor het vervaardigen van paroxetine.
CN1141318C (zh) 2001-02-28 2004-03-10 中国医学科学院血液学研究所 人促血液血管细胞生成素及其制造方法
WO2003010205A1 (en) * 2001-07-26 2003-02-06 Duke University Medical Center Genes induced by hypoxia
HUE029170T2 (en) * 2004-07-20 2017-03-28 Genentech Inc Preparations and methods for the use of angiopoietin-like protein 4
SI1771474T1 (sl) 2004-07-20 2010-06-30 Genentech Inc Inhibitorji angiopoetinu podobnega proteina kombinacije in njihova uporaba

Also Published As

Publication number Publication date
AU2006204001A1 (en) 2006-07-13
EA016185B1 (ru) 2012-03-30
EP1846452B1 (en) 2014-08-06
JP2008526857A (ja) 2008-07-24
WO2006074228A1 (en) 2006-07-13
ZA200705980B (en) 2009-01-28
CN101128485B (zh) 2012-09-26
IL184235A (en) 2012-10-31
KR101387781B1 (ko) 2014-04-21
US7655762B2 (en) 2010-02-02
BRPI0606432A2 (pt) 2009-06-30
CN101128485A (zh) 2008-02-20
US20120171217A1 (en) 2012-07-05
KR20070107696A (ko) 2007-11-07
IL184235A0 (en) 2007-10-31
EA200701452A1 (ru) 2008-02-28
AU2006204001B2 (en) 2011-06-16
JP5366406B2 (ja) 2013-12-11
MX2007008256A (es) 2007-12-06
CA2594233A1 (en) 2006-07-13
US8591891B2 (en) 2013-11-26
EP1846452A1 (en) 2007-10-24
CA2594233C (en) 2015-02-24
US20060222645A1 (en) 2006-10-05
US8092796B2 (en) 2012-01-10
US20110008359A1 (en) 2011-01-13

Similar Documents

Publication Publication Date Title
NO20092215L (no) Monoklonale antistoffer mot ANGPTL3
EA200701452A1 (ru) Моноклональные антитела против подобного ангиопоэтину белка 4 (angptl 4)
PT1766093E (pt) Anticorpos contra toxinas de clostridium difficile e utilizações dos mesmos
MX2018005512A (es) Agentes de union de esclerostina.
LTPA2017040I1 (lt) Antikūnai prieš CD38 antigeną, skirti išsėtinės mielomos gydymui
DK1629011T3 (da) Humane anti-humane-DC3-bindingsmolekyler
WO2003100033A3 (en) ANTI-αvβ6 ANTIBODIES
BR0315161A (pt) Anticorpo isolado, polinicleotìdeo isolado, vetor, célula hospedeira, método de produzir um anticorpo, e, composição
MX348432B (es) Epitopes.
AR083747A1 (es) Anticuerpos anti-il-23
CR9471A (es) Anticuerpos de p-caderina
CL2008001258A1 (es) Kit de vacuna que comprende al menos nueve conjugados de sacaridos de antgenos hb o hib, donde al menos 2-7 son con la proteina transportadora crm, siendo dicho kit adecuado para usar en su calendario de inmunizacion primaria; vacuna combinada adecuada para la inmunizacion primaria.
NZ592432A (en) Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1)
CY1113309T1 (el) Συνθεσεις και μεθοδοι χρησιμοποιωντας αντι-cs1 αντισωματα για να θεραπευεται πολλαπλο μυελωμα
WO2007116360A3 (en) Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
WO2008134724A3 (en) Methods for administering anti-il-5 antibodies
WO2009008916A3 (en) Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
NO20092743L (no) Antistoffer mot CD200R
AR073515A1 (es) Regulacion de la respuesta en plantas a la falta de nitrogeno
DK1861711T3 (da) Anvendelse af MGC4504
CR20140081A (es) Agentes de fijación

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application